已收盘 12-19 16:00:00 美东时间
+0.180
+0.58%
(来源:药剂Talks) 下一代肿瘤“药王”,极有可能诞生于PD-(L)1 Plus领域。 以K药为代表的PD-1单抗,开启了一代IO(肿瘤免疫治疗)时代,但...
09-04 07:52
出品/联商网&搜铺网 撰文/灰灰 商业竞争从来不是一场只看速度的短跑,而是一场考验耐力的马拉松。当潮水褪去,企业的核心竞争力,终归要回到稳固的根基上...
08-18 17:01
MEDIROM Healthcare Technologies Inc. announced on June 4, 2025, that it has regained compliance with Nasdaq’s minimum bid price requirement of $1.00 per share for its ADSs, as the closing bid price met or exceeded $1.00 for 10 consecutive business days from May 20 to June 3, 2025. The company, which operates over 300 wellness salons in Japan and focuses on health tech innovations, now maintains listing compliance.
06-05 18:02